How it works:
Liraglutide is a GLP-1 analogue. It enhances insulin release when blood glucose is high, suppresses glucagon secretion, and delays gastric emptying. This leads to better glycaemic control and appetite reduction.
Recommended for:
Research and evidence:
Large clinical programmes (LEAD, SCALE) confirmed liraglutide’s efficacy in reducing HbA1c, lowering body weight and improving cardiometabolic outcomes.
Administered subcutaneously once daily, preferably at the same time each day. The dose is selected individually by a physician based on tolerance and glucose levels.
Adverse effects: